Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose
โ Scribed by P. J. McNamara; K. Stoeckel; W. H. Ziegler
- Publisher
- Springer
- Year
- 1982
- Tongue
- English
- Weight
- 490 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Dolasetron, AnzemetTM, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokin
for assistance in the statistical evaluation of some of the results obtained from experimentation with mitochondria and also to the National Cancer Institute, Bethesda, Md., which undertook the antineoplastic evaluation of some of the compounds reported in this investigation.